Iteria Biopharma Prostate Cancer Program
Prostate Cancer
Pre-clinicalActive
Key Facts
About GalChimia
GalChimia is a privately-held, revenue-generating service provider in the small molecule and drug delivery sectors. Its core business is offering high-end custom chemical synthesis, chiral separations, and process chemistry services to pharmaceutical and biotech companies, leveraging deep expertise in complex multi-step organic synthesis. The company demonstrates scientific credibility through peer-reviewed publications and conference participation, and has spun out a biotech venture, Iteria Biopharma, to develop its own internal programs. Its outlook is tied to the sustained demand for outsourced chemistry expertise in drug discovery and development.
View full company profileOther Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| MagSense™ PSMA Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |